Description
BSE revokes the suspension in trading of equity shares of Rekvina Laboratories Limited (Scrip Code: 526075), allowing normal trading to resume.
Summary
BSE has revoked the suspension in trading of equity shares of Rekvina Laboratories Limited (Scrip Code: 526075, ISIN: INE092O01028). The company, engaged in the pharmaceutical industry providing quality medication at affordable prices, can now resume normal trading on the exchange.
Key Points
- Trading suspension revoked for Rekvina Laboratories Limited
- Scrip Code: 526075
- ISIN: INE092O01028
- Company operates in pharmaceutical industry
- Registered office located in Vadodara, Gujarat
- Manufacturing plant at GIDC Estate, Waghodia, Vadodara
- Group company: Radiant Parenterals Limited
- Current operational status: Active
- Managing Director: Amit Mukesh Shah (DIN: 01993211)
- Company Secretary: Deepak Khandelwal
- Auditor: M/s. Y.M. Shah & Co. (FRN: 114124W) for period 2024-25 to 2028-29
- Previous auditor: M/s. Jigar Adhyaru & Co. (2019-20 to 2023-24)
Regulatory Changes
No regulatory changes are introduced by this circular. This is a revocation of a previously imposed trading suspension.
Compliance Requirements
- Company has paid listing fees to BSE
- Company maintains active operational status
- Auditor change was conducted in compliance with statutory term completion requirements
Important Dates
Circular Date: December 30, 2025
Impact Assessment
Market Impact: Medium - Trading resumption allows shareholders to trade their holdings and provides liquidity to the scrip. This is positive for existing shareholders who were unable to exit positions during suspension.
Operational Impact: The company can now access capital markets normally and its shares will be available for trading, improving market confidence in the company’s compliance status.
Investor Impact: Positive for existing investors who can now trade their holdings. The revocation suggests the company has addressed the issues that led to the original suspension.
Impact Justification
Revocation of trading suspension is significant for shareholders and traders of Rekvina Laboratories as it allows normal trading to resume, but has limited broader market impact as it affects a single scrip.